Glenmede Trust’s Unity Biotechnology UBX Stock Holding History

Glenmede Trust’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-9	Closed	–	–	2588
2020 Q2	$0	Buy	+9	New	+$667	﹤0.01%	2621

Other funds holding UBX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Glenmede Trust's UBX Position: Q3 2020 in Review

Glenmede Trust sold out of Unity Biotechnology (UBX) in Q3 2020, closing a stake of 9 shares.

Glenmede Trust first reported a position in UBX in Q2 2020 and held it in 1 quarter. The position peaked at $0 in Q2 2020. 79 funds tracked by Wall St. Rank hold UBX as of Q3 2020.

Glenmede Trust reported no remaining Unity Biotechnology position as of Q3 2020 after selling out during the quarter.
Glenmede Trust sold 9 Unity Biotechnology shares in Q3 2020.
Glenmede Trust first reported a position in Unity Biotechnology in Q2 2020 and held it in 1 quarter.
Glenmede Trust's Unity Biotechnology position peaked at $0 in Q2 2020.
79 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2020.

Based on Glenmede Trust's 13F filing for Q3 2020, filed 16 Nov 2020.